{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Carcinoma+of+Head%2FNeck&page=41", "query": { "condition": "Carcinoma of Head/Neck", "page": 41 }, "page_size": 10 }, "pagination": { "page": 41, "page_size": 10, "total_count": 1994, "total_pages": 200, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Carcinoma+of+Head%2FNeck&page=42&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Carcinoma+of+Head%2FNeck&page=40&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-21T14:34:18.503Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00022217", "title": "Cisplatin-Epinephrine Injectable Gel Plus Paclitaxel and Carboplatin in Treating Patients With Recurrent Head and Neck Cancer", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Head and Neck Cancer" ], "interventions": [ { "name": "carboplatin", "type": "DRUG" }, { "name": "cisplatin-e therapeutic implant", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Matrix Pharmaceutical", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "2000-11", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-12-18", "last_synced_at": "2026-10-21T14:34:18.503Z", "location_count": 4, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Evanston, Illinois + 1 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Evanston", "state": "Illinois" }, { "city": "Shreveport", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT00022217" }, { "nct_id": "NCT03049358", "title": "Olfactory Training in Improving Sense of Smell After Radiation Therapy in Patients With Paranasal Sinus or Nasopharyngeal Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Stage 0 Nasopharyngeal Carcinoma", "Stage 0 Paranasal Sinus Cancer", "Stage I Nasopharyngeal Carcinoma", "Stage I Paranasal Sinus Cancer", "Stage II Nasopharyngeal Carcinoma", "Stage II Paranasal Sinus Cancer", "Stage IIA Nasopharyngeal Carcinoma", "Stage IIB Nasopharyngeal Carcinoma", "Stage III Nasopharyngeal Carcinoma", "Stage III Paranasal Sinus Cancer", "Stage IV Nasopharyngeal Carcinoma", "Stage IV Paranasal Sinus Cancer", "Stage IVA Nasopharyngeal Carcinoma", "Stage IVA Paranasal Sinus Cancer", "Stage IVB Nasopharyngeal Carcinoma", "Stage IVB Paranasal Sinus Cancer", "Stage IVC Nasopharyngeal Carcinoma", "Stage IVC Paranasal Sinus Cancer" ], "interventions": [ { "name": "Physiologic Testing", "type": "OTHER" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Sham Intervention", "type": "PROCEDURE" }, { "name": "Therapeutic Procedure", "type": "PROCEDURE" }, { "name": "rose essential oil", "type": "OTHER" }, { "name": "lemon essential oil", "type": "OTHER" }, { "name": "clove essential oil", "type": "OTHER" }, { "name": "eucalyptus essential oil", "type": "OTHER" }, { "name": "canola oil placebo", "type": "OTHER" } ], "intervention_types": [ "OTHER", "PROCEDURE" ], "sponsor": "Stanford University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": null, "sex": "ALL", "summary": "19 Years and older" }, "enrollment_count": 15, "start_date": "2016-12", "completion_date": "2018-10", "has_results": false, "last_update_posted_date": "2019-02-05", "last_synced_at": "2026-10-21T14:34:18.503Z", "location_count": 1, "location_summary": "Palo Alto, California", "locations": [ { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03049358" }, { "nct_id": "NCT05551117", "title": "A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Castration-Resistant Prostatic Cancer", "Androgen-Independent Prostatic Cancer", "Androgen-Insensitive Prostatic Cancer", "Androgen-Resistant Prostatic Cancer", "Hormone Refractory Prostatic Cancer", "Anal Cancer", "Anal Neoplasm", "Carcinoma, Squamous Cell of Head and Neck", "Head and Neck Squamous Cell Carcinoma", "Laryngeal Squamous Cell Carcinoma", "Oral Squamous Cell Carcinoma", "Malignant Melanoma", "Melanoma", "Non-small Cell Lung Cancer", "Non-small Cell Carcinoma", "Small-cell Lung Cancer", "Small Cell Carcinoma" ], "interventions": [ { "name": "vobramitamab duocarmazine 2.0 mg (Arm A)", "type": "BIOLOGICAL" }, { "name": "vobramitamab duocarmazine 2.7 mg (Arm B)", "type": "BIOLOGICAL" }, { "name": "vobramitamab duocarmazine", "type": "BIOLOGICAL" }, { "name": "Abiraterone", "type": "DRUG" }, { "name": "Enzalutamide", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "MacroGenics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 192, "start_date": "2023-06-13", "completion_date": "2025-01-23", "has_results": true, "last_update_posted_date": "2026-02-09", "last_synced_at": "2026-10-21T14:34:18.503Z", "location_count": 14, "location_summary": "Fountain Valley, California • Los Angeles, California • Jacksonville, Florida + 11 more", "locations": [ { "city": "Fountain Valley", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Orange City", "state": "Florida" }, { "city": "Covington", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT05551117" }, { "nct_id": "NCT01534897", "title": "Re-differentiation of Radioiodine-Refractory BRAF V600E-mutant Papillary Thyroid Carcinoma With GSK2118436", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Papillary Thyroid Carcinoma" ], "interventions": [ { "name": "GSK2118436", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2012-07", "completion_date": "2014-03", "has_results": true, "last_update_posted_date": "2017-03-15", "last_synced_at": "2026-10-21T14:34:18.503Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01534897" }, { "nct_id": "NCT05077709", "title": "IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lung Cancer Non Small Cell", "Head and Neck Squamous Cell Carcinoma", "Urothelial Carcinoma Bladder" ], "interventions": [ { "name": "IO102-IO103 in combination with pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "IO Biotech", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 63, "start_date": "2022-04-11", "completion_date": "2026-02-08", "has_results": true, "last_update_posted_date": "2026-04-08", "last_synced_at": "2026-10-21T14:34:18.503Z", "location_count": 9, "location_summary": "Duarte, California • Sacramento, California • San Diego, California + 6 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Orange City", "state": "Florida" }, { "city": "The Bronx", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05077709" }, { "nct_id": "NCT03144778", "title": "Durvalumab With or Without Tremelimumab in Treating Participants With Stage II-IVA Oropharyngeal Squamous Cell Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Stage II Oropharyngeal Squamous Cell Carcinoma AJCC v6 and v7", "Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7", "Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7" ], "interventions": [ { "name": "Durvalumab", "type": "BIOLOGICAL" }, { "name": "Tremelimumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 39, "start_date": "2017-07-12", "completion_date": "2021-03-15", "has_results": false, "last_update_posted_date": "2021-03-18", "last_synced_at": "2026-10-21T14:34:18.503Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03144778" }, { "nct_id": "NCT02201355", "title": "Hypofractionated Reduced-Volume Chemoradiation for T1/2N0-2 SCC Head and Neck", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Squamous Cell Carcinoma of the Head and Neck T1/2N0-2" ], "interventions": [ { "name": "Intensity Modulated Radiotherapy", "type": "RADIATION" } ], "intervention_types": [ "RADIATION" ], "sponsor": "University of Texas Southwestern Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 8, "start_date": "2014-09-18", "completion_date": "2020-05-15", "has_results": false, "last_update_posted_date": "2021-02-02", "last_synced_at": "2026-10-21T14:34:18.503Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02201355" }, { "nct_id": "NCT00507858", "title": "Pemetrexed (Alimta) in Patients With Head and Neck Squamous Cell Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Head and Neck Cancer" ], "interventions": [ { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2005-09", "completion_date": "2011-09", "has_results": false, "last_update_posted_date": "2011-09-23", "last_synced_at": "2026-10-21T14:34:18.503Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00507858" }, { "nct_id": "NCT05537740", "title": "A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors" ], "interventions": [ { "name": "BAY3375968", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 129, "start_date": "2022-10-11", "completion_date": "2027-05-04", "has_results": false, "last_update_posted_date": "2026-07-07", "last_synced_at": "2026-10-21T14:34:18.503Z", "location_count": 4, "location_summary": "Chicago, Illinois • Chapel Hill, North Carolina • San Antonio, Texas + 1 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "San Antonio", "state": "Texas" }, { "city": "West Valley City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT05537740" }, { "nct_id": "NCT05889091", "title": "A Study of the Use of Fat Flap Reconstruction to Reduce Neck Injury After Cancer Treatment", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Head and Neck Squamous Cell Carcinoma" ], "interventions": [ { "name": "HRQOL instruments", "type": "OTHER" }, { "name": "LENT SOMA instrument", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2023-05-16", "completion_date": "2027-05-16", "has_results": false, "last_update_posted_date": "2026-06-03", "last_synced_at": "2026-10-21T14:34:18.503Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05889091" } ] }